Grid Therapeutics is planning to start trials of its lead cancer immunotherapy next year after raising $5 million in second-round financing. The antibody drug, called GT103, is thought to work by ...
COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present ...
In the last decade, there has been a paradigm shift in cancer treatment. Dr. Andrew L. Pecora, chief innovations officer, professor and vice president of cancer services at John Theurer Cancer Center ...
Immunotherapy innovation is saving the lives of cancer patients across the country, while researchers continue to break new ground in this growing oncology field. When Sameek Roychowdhury, MD, PhD, ...
UCLA is the latest institution to join Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S. Through the I-O RPM program, BMS and the David Geffen ...
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Celsus Therapeutics and Volution Immuno Pharmaceuticals SA have announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno Pharmaceuticals ...
Deerfield Management is leading a $75 million round for a new biotech startup dubbed Akari Therapeutics, which was created out of Celsus Therapeutics' recent acquisition of Volution Immuno ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback